COO
Price
$74.20
Change
-$3.96 (-5.07%)
Updated
Apr 4, 11:39 AM (EDT)
Capitalization
19.72B
55 days until earnings call
DXCM
Price
$61.80
Change
-$6.34 (-9.30%)
Updated
Apr 3 closing price
Capitalization
53.47B
20 days until earnings call
Ad is loading...

COO vs DXCM

Header iconCOO vs DXCM Comparison
Open Charts COO vs DXCMBanner chart's image
Cooper Companies (The)
Price$74.20
Change-$3.96 (-5.07%)
Volume$14.24K
Capitalization19.72B
DexCom
Price$61.80
Change-$6.34 (-9.30%)
Volume$5.4M
Capitalization53.47B
COO vs DXCM Comparison Chart
Loading...
COO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COO vs. DXCM commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Buy and DXCM is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (COO: $78.17 vs. DXCM: $61.80)
Brand notoriety: COO and DXCM are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: COO: 126% vs. DXCM: 138%
Market capitalization -- COO: $19.72B vs. DXCM: $53.47B
COO [@Medical Specialties] is valued at $19.72B. DXCM’s [@Medical Specialties] market capitalization is $53.47B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COO’s FA Score shows that 0 FA rating(s) are green whileDXCM’s FA Score has 0 green FA rating(s).

  • COO’s FA Score: 0 green, 5 red.
  • DXCM’s FA Score: 0 green, 5 red.
According to our system of comparison, DXCM is a better buy in the long-term than COO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COO’s TA Score shows that 5 TA indicator(s) are bullish while DXCM’s TA Score has 5 bullish TA indicator(s).

  • COO’s TA Score: 5 bullish, 3 bearish.
  • DXCM’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, COO is a better buy in the short-term than DXCM.

Price Growth

COO (@Medical Specialties) experienced а -8.01% price change this week, while DXCM (@Medical Specialties) price change was -11.04% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.65%. For the same industry, the average monthly price growth was +1.31%, and the average quarterly price growth was +1.17%.

Reported Earning Dates

COO is expected to report earnings on May 29, 2025.

DXCM is expected to report earnings on Apr 24, 2025.

Industries' Descriptions

@Medical Specialties (-4.65% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DXCM($53.5B) has a higher market cap than COO($19.7B). DXCM has higher P/E ratio than COO: DXCM (106.11) vs COO (68.09). COO YTD gains are higher at: -14.968 vs. DXCM (-20.535). DXCM (917M) and COO (895M) have comparable annual earnings (EBITDA) . DXCM has more cash in the bank: 2.72B vs. COO (135M). DXCM has less debt than COO: DXCM (2.59B) vs COO (2.77B). COO (3.67B) and DXCM (3.62B) have equivalent revenues.
COODXCMCOO / DXCM
Capitalization19.7B53.5B37%
EBITDA895M917M98%
Gain YTD-14.968-20.53573%
P/E Ratio68.09106.1164%
Revenue3.67B3.62B101%
Total Cash135M2.72B5%
Total Debt2.77B2.59B107%
FUNDAMENTALS RATINGS
COO vs DXCM: Fundamental Ratings
COO
DXCM
OUTLOOK RATING
1..100
856
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8335
PRICE GROWTH RATING
1..100
6364
P/E GROWTH RATING
1..100
9096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COO's Valuation (76) in the Medical Specialties industry is in the same range as DXCM (79). This means that COO’s stock grew similarly to DXCM’s over the last 12 months.

COO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXCM (100). This means that COO’s stock grew similarly to DXCM’s over the last 12 months.

DXCM's SMR Rating (35) in the Medical Specialties industry is somewhat better than the same rating for COO (83). This means that DXCM’s stock grew somewhat faster than COO’s over the last 12 months.

COO's Price Growth Rating (63) in the Medical Specialties industry is in the same range as DXCM (64). This means that COO’s stock grew similarly to DXCM’s over the last 12 months.

COO's P/E Growth Rating (90) in the Medical Specialties industry is in the same range as DXCM (96). This means that COO’s stock grew similarly to DXCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COODXCM
RSI
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
59%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
60%
MACD
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 9 days ago
62%
Bullish Trend 19 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 8 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
63%
Aroon
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
70%
View a ticker or compare two or three
Ad is loading...
COO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EVRI13.65-0.07
-0.51%
Everi Holdings
YUMC52.63-0.65
-1.22%
Yum China Holdings
SDOT2.56-0.04
-1.54%
Sadot Group Inc
CDZI2.67-0.28
-9.64%
CADIZ
AZTA31.30-4.11
-11.61%
Azenta

DXCM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then CERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-9.30%
CERS - DXCM
42%
Loosely correlated
-7.86%
IRMD - DXCM
34%
Loosely correlated
-4.18%
AORT - DXCM
33%
Loosely correlated
-3.63%
ACRS - DXCM
33%
Loosely correlated
-3.25%
COO - DXCM
32%
Poorly correlated
-3.77%
More